Health
ACROFAN – ACROFAN USA
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial e…
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection
First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September
NEW BRUNSWICK, New Jersey, July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the v…
-
Noosa News23 hours agoNorth Lakes home erupts in flames as woman rushed from burning house with injuries
-
Noosa News23 hours agoChild safety boss says Unify IT system was launched for budgetary reasons
-
General22 hours ago‘Folly’ of nuclear submarines plan floated
-
Noosa News23 hours agoBroncos respond to Storm star Stefano Utoikamanu’s ‘stuck up’ barb ahead of NRL grand final